Want to see GHRS full AI Analyst Report?

GH Research (GHRS) Price & Analysis

374 Followers

GHRS Stock Chart & Stats

$18.34

-$0.22(-2.41%)

At close: Jan 08 4:00 PM EST

$18.34

-$0.22(-2.41%)

Day’s Range― - ―

52-Week Range$11.32 - $31.00

Previous CloseN/A

Volume14.35K

Average Volume (3M)289.15K

Market Cap

$1.97B

Enterprise Value$605.31

Total Cash (Recent Filing)$267.32M

Total Debt (Recent Filing)$432.00K

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 26, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.92

Shares Outstanding68,557,175

10 Day Avg. Volume364,444

30 Day Avg. Volume289,153

Financial Highlights & Ratios

PEG Ratio-3.01

Price to Book (P/B)2.77

Price to Sales (P/S)0.00

P/FCF Ratio-17.75

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$41.67

Price Target Upside127.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.4

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage & Sizable EquityA very low debt load combined with roughly $263M of equity provides structural financial optionality: it lowers short-term refinancing risk, supports sustained R&D spend, and gives management flexibility to fund trials or strike partnerships without immediate liquidity stress.

Positive Phase 2a Clinical SignalRapid, large-magnitude efficacy and remission in the Phase 2a postpartum study, plus Phase 2b visibility, materially de-risks GH001's development narrative. Demonstrated fast action and functional gains strengthen the company's scientific positioning and support regulatory and investigator engagement long term.

Established Access To CapitalA successful $111M underwritten raise (and an active registration shelf) shows credible market access and investor support, increasing runway to advance trials and pre-commercial work. Structural access to public capital reduces near-term financing urgency for program progression.

Bears Say

No Revenue & Widening LossesThe company remains pre-revenue with materially widening operating losses over several years. This structural lack of commercial cash inflows means long-term viability hinges on clinical success, external funding, or partnerships; sustained negative results would erode capital and strategic options.

Persistent Negative Operating Cash FlowConsistently large negative operating and free cash flow reflects heavy R&D and G&A burn. Even with intermittent raises, the structural cash-burn profile necessitates repeated financing or partnering, which can constrain timelines, increase costs of capital, and force trade-offs in clinical prioritization.

Structural Dilution Risk From Equity TapsAn active $200M ATM facility and prior offerings provide vital liquidity but create persistent dilution risk if tapped repeatedly. Over time, frequent equity issuance can reduce per-share economics and investor alignment unless offset by material clinical or commercialization milestones that increase intrinsic value.

GH Research News

Helus Pharma price target lowered to $45 from $48 at Guggenheim

Guggenheim lowered the firm’s price target on Helus Pharma (HELP) to $45 from $48 and keeps a Buy...

3d ago

LLY

ATAI

AtaiBeckley downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded AtaiBeckley (ATAI) to Hold from Buy after Eli Lilly (LLY) agreed to acquire the company for...

4d ago

ATAI

CMPS

FDA announces availability of final guidance for psychedelic drug research

The agency said, “The Food and Drug Administration is announcing the availability of a final guidance for industry...

5d ago

ATAI

CMND

VA, HHS sign MOU to improve cooperation on psychedelic drug trials

The Department of Veterans Affairs and Department of Health and Human Services signed a memorandum of understanding to...

7d ago

ATAI

CMPS

Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors

Jefferies notes that on September 14, the FDA will host a public hearing to discuss “issues” associated with...

7d ago

ATAI

CMPS

GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM

GH Research ( ($GHRS) ) just unveiled an announcement. On June 25, 2026, GH Research PLC held its...

24d ago

GHRS

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

CMND

ENVB

GH Research announces publication of Phase 2a results for mebufotenin

GH Research (GHRS) announced the publication of the full results from its Phase 2a trial in postpartum depression...

2M ago

GHRS

GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001

An update from GH Research ( ($GHRS) ) is now available. On June 4, 2026, GH Research PLC...

2M ago

GHRS

Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

CMND

CMPS

GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026

GH Research ( ($GHRS) ) has provided an announcement. GH Research PLC will showcase new Phase 2b data...

2M ago

GHRS

GH Research price target lowered to $65 from $70 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on GH Research (GHRS) to $65 from $70 and keeps a...

2M ago

GHRS

GH Research price target raised to $35 from $25 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on GH Research (GHRS) to $35 from $25 and keeps an...

2M ago

GHRS

GH Research Launches $200 Million At-the-Market Share Offering With Stifel

An announcement from GH Research ( ($GHRS) ) is now available. On May 14, 2026, GH Research PLC...

2M ago

GHRS

GHRS FAQ

What was Gh Research Plc’s price range in the past 12 months?

Gh Research Plc lowest stock price was $11.32 and its highest was $31.00 in the past 12 months.

What is Gh Research Plc’s market cap?

Gh Research Plc’s market cap is $1.97B.

When is Gh Research Plc’s upcoming earnings report date?

Gh Research Plc’s upcoming earnings report date is Aug 26, 2026 which is in 37 days.

How were Gh Research Plc’s earnings last quarter?

Gh Research Plc released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.293 by -$0.017.

Is Gh Research Plc overvalued?

According to Wall Street analysts Gh Research Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gh Research Plc pay dividends?

Gh Research Plc does not currently pay dividends.

What is Gh Research Plc’s EPS estimate?

Gh Research Plc’s EPS estimate is -0.32.

How many shares outstanding does Gh Research Plc have?

Gh Research Plc has 68,557,175 shares outstanding.

What happened to Gh Research Plc’s price movement after its last earnings report?

Gh Research Plc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.293. Following the earnings report the stock price went up 1.508%.

Which hedge fund is a major shareholder of Gh Research Plc?

Currently, no hedge funds are holding shares in GHRS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

GH Research Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-14.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gh Research Plc

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

GH Research (GHRS) Earnings & Revenues

Historic Earnings Reports

GHRS Stock 12 Month Forecast

Average Price Target

$41.67

▲(127.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","66":"$66","24.75":"$24.8","38.5":"$38.5","52.25":"$52.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,24.75,38.5,52.25,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.42,29.38769230769231,32.355384615384615,35.323076923076925,38.29076923076923,41.25846153846154,44.22615384615385,47.19384615384615,50.16153846153846,53.12923076923077,56.096923076923076,59.06461538461539,62.0323076923077,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.42,27.592820512820513,28.765641025641028,29.93846153846154,31.111282051282053,32.28410256410257,33.456923076923076,34.62974358974359,35.802564102564105,36.97538461538461,38.14820512820513,39.32102564102564,40.49384615384615,{"y":41.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.42,26.849230769230772,27.27846153846154,27.70769230769231,28.13692307692308,28.566153846153846,28.995384615384616,29.424615384615386,29.853846153846156,30.283076923076923,30.712307692307693,31.14153846153846,31.57076923076923,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.01,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.72,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.83,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.42,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >